158 related articles for article (PubMed ID: 28182356)
1. Association between N-Acetyltransferase 2 Polymorphism and Bladder Cancer Risk: a Meta-Analysis in a Single Ethnic Group.
Xu WJ; Wen LP; Jiang XX; Ye LY; Meng FH; Guan S; Qian YJ; Wei JF
Clin Lab; 2017 Feb; 63(2):287-293. PubMed ID: 28182356
[TBL] [Abstract][Full Text] [Related]
2. Differential association for N-acetyltransferase 2 genotype and phenotype with bladder cancer risk in Chinese population.
Quan L; Chattopadhyay K; Nelson HH; Chan KK; Xiang YB; Zhang W; Wang R; Gao YT; Yuan JM
Oncotarget; 2016 Jun; 7(26):40012-40024. PubMed ID: 27223070
[TBL] [Abstract][Full Text] [Related]
3. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N
Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301
[TBL] [Abstract][Full Text] [Related]
4. Association Between N-acetyltransferase 2 Polymorphism and Bladder Cancer Risk: Results From Studies of the Past Decade and a Meta-Analysis.
Wu H; Wang X; Zhang L; Mo N; Lv Z
Clin Genitourin Cancer; 2016 Apr; 14(2):122-9. PubMed ID: 26585839
[TBL] [Abstract][Full Text] [Related]
5. N-acetyltransferase 2 polymorphism is associated with bladder cancer risk: An updated meta-analysis based on 54 case-control studies.
Song Y; Qi X; Liu X
Gene; 2020 Oct; 757():144924. PubMed ID: 32622992
[TBL] [Abstract][Full Text] [Related]
6. NAT2 slow acetylation and bladder cancer in workers exposed to benzidine.
Carreón T; Ruder AM; Schulte PA; Hayes RB; Rothman N; Waters M; Grant DJ; Boissy R; Bell DA; Kadlubar FF; Hemstreet GP; Yin S; LeMasters GK
Int J Cancer; 2006 Jan; 118(1):161-8. PubMed ID: 16003747
[TBL] [Abstract][Full Text] [Related]
7. N-acetyltransferase 2 phenotype, occupation, and bladder cancer risk: results from the EPIC cohort.
Pesch B; Gawrych K; Rabstein S; Weiss T; Casjens S; Rihs HP; Ding H; Angerer J; Illig T; Klopp N; Bueno-de-Mesquita B; Ros MM; Kaaks R; Chang-Claude J; Roswall N; Tjønneland A; Overvad K; Clavel-Chapelon F; Boutron-Ruault MC; Dossus L; Boeing H; Weikert S; Trichopoulos D; Palli D; Sieri S; Tumino R; Panico S; Quirós JR; González C; Sánchez MJ; Dorronsoro M; Navarro C; Barricarte A; Ljungberg B; Johansson M; Ulmert D; Ehrnström R; Khaw KT; Wareham N; Key TJ; Ferrari P; Romieu I; Riboli E; Brüning T; Vineis P
Cancer Epidemiol Biomarkers Prev; 2013 Nov; 22(11):2055-65. PubMed ID: 24092628
[TBL] [Abstract][Full Text] [Related]
8. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.
Selinski S; Blaszkewicz M; Ickstadt K; Hengstler JG; Golka K
Arch Toxicol; 2013 Dec; 87(12):2129-39. PubMed ID: 24221535
[TBL] [Abstract][Full Text] [Related]
9. Polymorphism of N-acetyltransferase 2 (NAT2) gene polymorphism in shanghai population: occupational and non-occupational bladder cancer patient groups.
Ma QW; Lin GF; Chen JG; Xiang CQ; Guo WC; Golka K; Shen JH
Biomed Environ Sci; 2004 Sep; 17(3):291-8. PubMed ID: 15602826
[TBL] [Abstract][Full Text] [Related]
10. NAT2 gene polymorphisms and endometriosis risk: A PRISMA-compliant meta-analysis.
Wei Z; Zhang M; Zhang X; Yi M; Xia X; Fang X
PLoS One; 2019; 14(12):e0227043. PubMed ID: 31881062
[TBL] [Abstract][Full Text] [Related]
11. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population.
Marcus PM; Vineis P; Rothman N
Pharmacogenetics; 2000 Mar; 10(2):115-22. PubMed ID: 10761999
[TBL] [Abstract][Full Text] [Related]
12. NAT2 polymorphisms combining with smoking associated with breast cancer susceptibility: a meta-analysis.
Zhang J; Qiu LX; Wang ZH; Wang JL; He SS; Hu XC
Breast Cancer Res Treat; 2010 Oct; 123(3):877-83. PubMed ID: 20180012
[TBL] [Abstract][Full Text] [Related]
13. Clarifying haplotype ambiguity of NAT2 in multi-national cohorts.
Selinski S; Blaszkewicz M; Agundez JA; Martinez C; Garcia-Martin E; Hengstler JG; Golka K
Front Biosci (Schol Ed); 2013 Jan; 5(2):672-84. PubMed ID: 23277078
[TBL] [Abstract][Full Text] [Related]
14. N-acetyltransferase 2 status and gastric cancer risk: a meta-analysis.
Yu J; Deng Y; Chen JP
Tumour Biol; 2014 Jul; 35(7):6861-5. PubMed ID: 25051916
[TBL] [Abstract][Full Text] [Related]
15. Modifying Effect of Smoking on GSTM1 and NAT2 in Relation to the Risk of Bladder Cancer in Mongolian Population: A Case-Control Study.
Avirmed S; Khuanbai Y; Sanjaajamts A; Selenge B; Dagvadorj BU; Ohashi M
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2479-2485. PubMed ID: 34452561
[TBL] [Abstract][Full Text] [Related]
16. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
Okkels H; Sigsgaard T; Wolf H; Autrup H
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
[TBL] [Abstract][Full Text] [Related]
17. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China.
Song DK; Xing DL; Zhang LR; Li ZX; Liu J; Qiao BP
Cancer Detect Prev; 2009; 32(5-6):416-23. PubMed ID: 19303722
[TBL] [Abstract][Full Text] [Related]
18. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction.
Marcus PM; Hayes RB; Vineis P; Garcia-Closas M; Caporaso NE; Autrup H; Branch RA; Brockmöller J; Ishizaki T; Karakaya AE; Ladero JM; Mommsen S; Okkels H; Romkes M; Roots I; Rothman N
Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):461-7. PubMed ID: 10815690
[TBL] [Abstract][Full Text] [Related]
19. Possible association of NAT2 polymorphism with laryngeal cancer risk: an evidence-based meta-analysis.
Ying XJ; Dong P; Shen B; Wang J; Wang S; Wang G
J Cancer Res Clin Oncol; 2011 Nov; 137(11):1661-7. PubMed ID: 21877196
[TBL] [Abstract][Full Text] [Related]
20. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk.
Hein DW
Oncogene; 2006 Mar; 25(11):1649-58. PubMed ID: 16550165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
